New lipid nanoparticles enable mRNA therapy for inflammatory bowel disease
Researchers developed MP2 lipid nanoparticles to deliver mRNA for treating inflammatory bowel disease.
Researchers developed lipid nanoparticles (LNPs) for rectal and lesion-localized mRNA delivery. These particles were formulated for inflammatory bowel disease (IBD).
The MP2 LNPs use a methylprednisolone-derived ionizable lipid. These MP2 LNPs showed a 15-fold higher delivery efficiency in vivo than the FDA approved SM102 LNPs. Lipid nanoparticles are formulations used for mRNA delivery.
When loaded with interleukin-35 (IL-35) mRNA, the MP2-IL-35 LNPs ameliorated colitis in acute and chronic IBD mouse models. This improved clinical scores and preserved colon length. It also reduced pro-inflammatory cytokines.
In ex vivo human colonic biopsies, MP2 LNPs enabled effective mRNA delivery in immune, epithelial and endothelial cells. In biopsies from patients with IBD, MP2-IL-35 LNPs significantly reshaped effector and regulatory T cell subsets.
Current treatments for IBD are limited by suboptimal efficacy and systemic toxicity. These findings support MP2-IL-35 LNPs as a promising mRNA therapy for IBD.
Key facts
- MP2 LNPs showed a 15-fold higher delivery efficiency in vivo than FDA approved SM102 LNPs.
- MP2-IL-35 LNPs ameliorated colitis in acute and chronic IBD mouse models.
- MP2-IL-35 LNPs significantly reshaped effector and regulatory T cell subsets in biopsies from IBD patients.